Collectively, these findings underscore the importance of PRMTs in shaping anti-tumor immunity and suggest that co-targeting PRMTs, especially PRMT1, may offer a promising approach to improve the efficacy of immune checkpoint therapies. This evidence concerns the gene PRMT1 and neoplasm.